NYSE
182.46USD
-11.40 (-5.88%)
We have scored 58 news catalysts on DaVita Inc. (DVA) over the past 12 months. The biggest single-day move next to one of them came Aug 3, 2026, when DVA closed −2.7%: “Quest Diagnostics Raises 2026 Outlook as Testing Demand Accelerates”. Coverage across the window leans positive (average ticker sentiment +0.33). Most of the impact sits in sector healthcare and earnings revision trend.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
11.8B
P/E
—
EPS
—
Beta
0.83
52W range
101-247.49
Day range
182.41–195.82
Open
195.46
Prev close
193.86
Volume
752.6K
Avg volume
826K
Dividend
0.00
IPO
1995-10-31
Analysts publish price targets on DVA, and they disagree. Where the share price actually sits among them shows which of their arguments the market is buying — and which it is ignoring.
10 analyst price targets from $194 to $270
as of 2026-09-04
The market is 17% below the median target — more cautious than the analysts.
The reconstruction
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about DaVita Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Suppliers, customers, partners and competitors of DaVita Inc., taken from what the news actually said about them rather than from a sector bucket. The count is how many articles established each link.
Latest scored catalyst for DVA: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
DaVita Inc. specializes in delivering essential kidney dialysis treatments and comprehensive renal care to individuals grappling with chronic kidney failure. The company primarily operates an extensive network of outpatient dialysis centers, supplementing this with services provided in hospital inpatient settings and within patients' homes. Beyond direct patient treatment, DaVita manages its own diagnostic laboratories, performing routine tests vital for dialysis patients, alongside other physician-ordered laboratory analyses specifically for those with end-stage renal disease (ESRD). The firm also offers administrative and management support to various other outpatient dialysis facilities. Its broad spectrum of offerings extends to chronic disease management programs, supporting a substantial patient cohort; by year-end 2021, this included 16,000 patients enrolled in risk-based integrated care models and an additional 7,000 in other integrated care arrangements. Further specialized services encompass vascular access interventions, clinical research initiatives, direct physician support, and a complete suite of holistic kidney care solutions. As of December 31, 2021, DaVita's footprint across the United States comprised 2,815 outpatient dialysis centers, collectively serving approximately 203,100 patients. Globally, the company operated 339 outpatient dialysis centers spread across ten countries outside the U.S., attending to roughly 39,900 patients. Moreover, it furnished acute inpatient dialysis services and related laboratory work in around 850 U.S. hospitals. Founded in 1994, DaVita Inc. maintains its headquarters in Denver, Colorado. The company rebranded to its current name in September 2016, having previously been known as DaVita HealthCare Partners Inc.
The price sits at the very bottom of the published analyst range, 17% below the median target and rejecting all eight bull cases, meaning the market expects DaVita's revenue and profit growth to fall well short of what the models project.
What the disagreement turns on
Can DaVita stabilize or grow its revenue per treatment and expand margins as one-time headwinds fade, or will declining commercial mix and stagnant volumes keep cash flow flat? The available data can measure treatment volumes via segment revenue history, but it cannot measure the crucial commercial payor pricing and mix shifts that drive profitability.
The price pays for
It declines to pay for
Written by a language model from the published models, the reported segments and a reverse-DCF — not a recommendation, and not a house view.
Claim by claim
